Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Spruce Biosciences (SPRB) EBITDA Margin (2023 - 2024)

Spruce Biosciences (SPRB) has disclosed EBITDA Margin for 2 consecutive years, with 3380.06% as the latest value for Q4 2024.

  • Quarterly EBITDA Margin fell 303706.0% to 3380.06% in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 7026.11% through Sep 2025, down 647100.0% year-over-year, with the annual reading at 1079.94% for FY2024, 61102.0% down from the prior year.
  • EBITDA Margin for Q4 2024 was 3380.06% at Spruce Biosciences, down from 1440.37% in the prior quarter.
  • The five-year high for EBITDA Margin was 343.0% in Q4 2023, with the low at 3380.06% in Q4 2024.